Achieving allocative efficiency in healthcare: nice in theory, not so NICE in Practice? |
|
Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al |
|
The authors’ reply |
|
Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. |
|
Cancer Drugs Fund 2.0: A Missed Opportunity? |
|
Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCT |
|
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models |
|
Constructing indirect utility models: some observations on the principles and practice of mapping to obtain health state utilities |
|
Continuing the multiple sclerosis risk sharing scheme is unjustified. |
|
Correlated Parameters and the Cholesky Decomposition |
|
Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists |
|
Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus |
|
Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population |
|
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine. |
|
Economic considerations in the provision of treatments for rare diseases. |
|
Economic Evaluation, Cost Effectiveness Analysis and Health Care Resource Allocation |
|
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer |
|
Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions |
|
Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation. |
|
Expected net present value of sample information: from burden to investment |
|
Hard choices: Reflections from the tomb of the unknown patient |
|
Health economics in drug development: efficient research to inform healthcare funding decisions |
|
Health state values for the HUI 2 descriptive system: results from a UK survey |
|
Health technology funding decision-making processes around the world: the same, yet different |
|
Incorporation of uncertainty in health economic modelling studies |
|
The Incremental Cost Effectiveness of Withdrawing Pulmonary Artery Catheters from Routine Use in Critical Care |
|
An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer |
|
Introduction to Markov Cost Effectiveness Models |
|
Is it time to revisit orphan drug policies? |
|
'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'. |
|
Low-value approvals and high prices might incentivize ineffective drug development |
|
Making a Markov Model Probabilistic |
|
Marketing of unproven stem cell-based interventions: A call to action |
|
Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and Mushlin |
|
Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT |
|
Modeling HUI 2 health state preference data using a nonparametric Bayesian method |
|
Navigating time and uncertainty in health technology appraisal: would a map help? |
|
The NICE cost-effectiveness threshold: what it is and what that means |
|
Objectivity and equity: clarity required. A response to Hill and Olson. |
|
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer |
|
Orphan drugs and the NHS: should we value rarity? |
|
A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE |
|
Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation |
|
Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier |
|
Probability Distributions for Effectiveness Parameters |
|
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate |
|
Response to Shmueli |
|
Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence |
|
Self-Harm Intervention: Family Therapy (SHIFT), a study protocol for a randomised controlled trial of family therapy versus treatment as usual for young people seen after a second or subsequent episode of self-harm |
|
Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines |
|
Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies? |
|
Show drugs work before selling them. |
|
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT |
|
Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment |
|
Some inconsistencies in NICE's consideration of social values. |
|
The STAR trial: can quality of life benefit offset any survival detriment? |
|
Stem cells and beta cell replacement therapy: a prospective health technology assessment study. |
|
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug |
|
To fund or not to fund: development of a decision-making framework for the coverage of new health technologies |
|
Uncertainty, Probabilistic Analysis and Outputs from Cost Effectiveness Analyses |
|
Understanding Harris' understanding of CEA: is cost effective resource allocation undone? |
|
Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product. |
|
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence |
|
Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis |
|
Use of visual analog scales in economic evaluation |
|
Using rank data to estimate health state utility models |
|
Value based pricing for NHS drugs: an opportunity not to be missed? |
|
Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework |
|
Value-engineered translation for regenerative medicine: meeting the needs of health systems. |
|
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. |
|
Value of Information in Health Technology Regulation and Reimbursement |
|
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected |
|
What evidence is there for the reimbursement of personalised medicine? |
|
Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement |
|